Skip to main content
Caplight Logo









Dayra Therapeutics

Dayra Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.dayratx.com/

Last Round

Series A

Nov 24, 2025

Total Funding Raised

$90M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Dayra Therapeutics is a biotechnology company that develops oral macrocyclic peptide therapeutics. The company combines its macrocycle discovery platform with computational design and modeling to create novel macrocyclic peptides that selectively target disease-relevant proteins, with the goal of expanding treatment options and improving patient outcomes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

macrocyclic peptidesoral peptidesmacrocycle discoveryoral biologicscomputational drug designin-silico drug discoverydrug discovery platformpharma partnershipsimmunology therapeuticspreclinical drug developmentAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dayra Therapeutics Comparables

Compare Dayra Therapeutics with similar companies based on industry and business-model similarity.

Dayra Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vilya
85%
Orbis Medicines
84%
Unnatural Products
81%

Dayra Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 24, 2025

Dayra Therapeutics Investors

Notable investors and investment history

Dayra Therapeutics investors
InvestorRounds
Versant VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 24, 2025

    $70M round led by Versant Ventures.

Dayra Therapeutics Filings

Explore SEC and related filing metadata, where available.

Dayra Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Dayra Therapeutics's valuation, stock price, and market status.

Is Dayra Therapeutics a public or private company?

Dayra Therapeutics is a private company.

What is the current stock price of Dayra Therapeutics?

Dayra Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Dayra Therapeutics worth (valuation)?

Valuation information for Dayra Therapeutics is not publicly available.

Can I buy Dayra Therapeutics stock?

Dayra Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Dayra Therapeutics's last funding round?

Dayra Therapeutics's most recent funding round was Series A on November 24, 2025.

Who are the main investors in Dayra Therapeutics?

Key investors in Dayra Therapeutics include Versant Ventures.

Will Dayra Therapeutics IPO soon?

No public IPO plans have been announced for Dayra Therapeutics.

How can I track Dayra Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Dayra Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range9
Year Founded2024
Last FundingNov 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?